Navigation Links
Immtech to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Date:11/5/2007

NEW YORK, Nov. 5 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) announced today that it will present at the Acumen BioFin(TM) Rodman & Renshaw 9th Annual Healthcare Conference.

On Tuesday, November 6 at 2:40 p.m. Eastern Time, Immtech is scheduled to present in the Hubbard Room, 5th floor, at the New York Palace Hotel in New York City.

Immtech will hold a conference call on Friday, November 9, at 3.00 p.m. (ET) to present an update on the Company's progress. The User Access Code is # 23641366. Investors and interested parties in the U.S. are invited to join the call by dialing (888) 338-8374 and callers outside the U.S. should call (706) 902-3163. To register, please call no later than 10 minutes prior to the scheduled start of the call. Information to access a recording of the conference call will be available starting on November 12 from the Immtech Pharmaceuticals website (http://www.immtechpharma.com).

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases, and the company is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African sleeping sickness), and a well-defined, expanding library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive worldwide licenses to certain patents, patent applications and technology for products derive
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
2. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
3. Chinese SFDA Grants Immtech Fast Track Status
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... ANGELES , Sept. 30, 2014 ... biopharmaceutical research and development company specializing in oncology, ... 2b clinical trial evaluating aldoxorubicin compared to topotecan ... (SCLC) who have relapsed or were refractory to ... the widely-used chemotherapeutic agent, doxorubicin. CytRx has received ...
(Date:9/29/2014)... et SAN DIEGO ... Company, Ltd. (ci-après désignée Daiichi Sankyo) (TSE : 4568) ... aujourd,hui la conclusion d,un accord de fusion définitif ... la totalité des actions ordinaires en circulation d,Ambit ... par le biais d,une offre publique d,achat qui ...
(Date:9/29/2014)... Sept. 29, 2014  Bob Pack, who lost his ... on the California Medical Association to immediately cease airing ... the San Jose Mercury News called "shamelessly deceptive" and ... wants voters to believe about the measure is wrong." ... Prop 46 requirement that doctors check California,s ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5
(Date:9/30/2014)... 30, 2014 AutoTex PINK ... iconic pink ribbon in support of breast cancer awareness ... for businesses and non-profits to “go pink” -- supporting ... AutoTex PINK is a woman-owned company that is among ... are committed to partnering with their customers to raise ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Teeth replacement ... Dental Art Institute in Oxnard and Thousand Oaks, Calif., ... and tomorrow to provide training on full mouth rehabilitation. ... work, placing implants, providing cosmetic dentistry, correcting bite issues, ... said. , Dr. Jivraj, who has traveled to India ...
(Date:9/30/2014)... Loffler Companies, an award winning and ... was recognized by BEI as the number one ... This prestigious rating means that Loffler Service Technicians ... an extended period following, optimizing user productivity and ... Services has been the trusted provider for unbiased ...
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 In ... commemorate breast cancer survivors and their courageous battles, Incredible ... to start afresh with PicoSure® by Cynosure. , ... blue or black tattoo is applied on their skin ... explains Dr. Sam Ebrahimi. “For many survivors, they decide ...
(Date:9/30/2014)... New York (PRWEB) September 30, 2014 ... Co-Founder of Hudson Allergy , will discuss how ... food allergies and other special dietary restrictions at the ... Restaurateurs & Food Service Professionals, October 21 in New ... on this incredibly important topic to such an engaged ...
Breaking Medicine News(10 mins):Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3Health News:Incredible Veins, Body & Skin Takes A Stand Against Breast Cancer With PicoSure® By Cynosure 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 3
... in a precipitous decline, David C. Dale, MD, FACP, ... joined with leading representatives of employers and consumers ... recruit and retain general internists and other primary care ... state of primary care medicine in the U.S., Dr. ...
... Save Vital Services for Frail Seniors and People ... of,homecare workers across the state are outraged by ... wages and benefits,which would force some of California,s ... into poverty. They pledged to save these vital,services ...
... 10,000 Sensual O Condom Packs Donation Marks the Launch ... 16 On Saturday, May 17th 2008, hip-hop,and R & ... "Everybody in the Club,Gettin, Tipsy," will be presenting the Urban ... over $50,000. The donation is,being made to promote the launch ...
... who would benefit most from chemo after surgery, study says ... 15 genes may help determine which patients with early-stage non-small ... the most from chemotherapy, a new study shows. , ... with less aggressive forms of the cancer who would be ...
... tropical storms,continue to batter the affected area of ... to diseases and other severe problems. Many,survivors still ... and,malnutrition are creating an increasingly dire situation., ... more help to,recover from this disaster and get ...
... Research Funding Per Death Drops More in 2007, ... three cancer deaths, the National Cancer Institute (NCI) invested,less ... cancer research in 2007,according to updated statistics issued by ... federal agencies with significant cancer research,programs -- Centers for ...
Cached Medicine News:Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:Everybody in the Club Scream O! 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Myanmar Cyclone Survivors Face New Challenges 2Health News:Lung Cancer Still Lowest in Federal Funding 2
... Elite II features a diagnostic ... of Glasgow,(UG) algorithm. Unlike competitive ... age, the UG,algorithm bases its ... gender, age, race, medication,and classification., ...
... test face is a LogMAR ... Landolt C in various orientations ... targets are presented at 10% ... useful for evaluating the low ...
The CSV-1000-1.5CPD is a special test face designed specifically for Food and Drug Administration clinical trials., ,At the recommended test distance of 8 feet, the gratings test one spatial frequenc...
... test face is used widely for screening ... LogMAR acuity from 20/10 to 20/100 and ... cycles/degree. , ,The patient can be easily ... acuity and contrast sensitivity. If a contrast ...
Medicine Products: